facebooktwitteryoutubelinkedin 
E-News | Jobs | Contact

dndi donate_button

Advocacy

Attention: open in a new window. PDFPrintE-mail

government sleeping_sickness

As part of its mission, DNDi advocates for enhanced political leadership, increased resources, and an enabling policy environment to stimulate research and development (R&D) for neglected diseases. DNDi actively advocates for sound policies that will enable greater needs-driven R&D, including appropriate incentives and financing mechanisms, innovative regulatory pathways that will expedite access, and open innovation approaches to intellectual property management that ensure the widest possible sharing of research knowledge and data.


U.S. POLICY

The U.S.'s Neglected Tropical Disease (NTD) Program, under the U.S. Agency for International Development (USAID), is the main U.S. government body addressing the urgent health needs of people suffering from NTDs.  Despite its helpful work, the USAID NTD Program includes only 5 of the world's 17 NTDs, and excludes the three NTDs with the highest death rates - African sleeping sickness, Chagas disease, and visceral leishmaniasis (kala azar) - which are the core diseases focused on by DNDi.

DNDi North America advocates for the inclusion of these deadly diseases, as well as all NTDs, into the U.S.'s NTD Program, and also calls for the U.S. government to fund late-stage drug and other product development for these fatal NTDs, as it does for other diseases such as HIV/AIDS, tuberculosis, and malaria.

Read an opinion piece by Rachel Cohen, Regional Executive Director of DNDi North America, calling for further U.S. government support for deadly NTDs: "The US Government and research and development for neglected tropical diseases: Most neglected patients still falling through the cracks"

DNDi North America advocacy to the U.S. government:

March 2013: DNDi North America testimony to the U.S. House of Representatives Committee on Appropriations, Subcommittee on State and Foreign Operations, requesting full funding of fiscal year 2014 (FY2014) U.S. NTD Program, investment in R&D for NTDs, and expansion of the USAID list of NTDs to include those with the highest death rates - sleeping sickness, Chagas disease, and leishmaniasis.

April 2012: DNDi North America letter to the U.S. Senate Committee on Appropriations, Subcommittee on State and Foreign Operations, requesting FY2013 U.S. NTD budget restoration and increase. In February 2012, the White House proposed its U.S. FY2013 budget, which targeted the NTD Program with a nearly 25% cut - one of the single largest percentage funding cuts in global health.

March 2012: DNDi North America testimony to the U.S. House of Representatives Committee on Appropriations, Subcommittee on State and Foreign Operations, requesting FY2013 U.S. NTD budget restoration and increase. In February 2012, the White House proposed its U.S. FY2013 budget, which targeted the NTD Program with a nearly 25% cut - one of the single largest percentage funding cuts in global health.

April 2011: DNDi North America testimony to the U.S. Senate Committee on Appropriations, Subcommittee on State, Foreign Operations, and Related Programs, emphasizing the urgent need for the USAID NTD Program to incorporate the NTDs with the highest death rates.


U.S. INSTITUTE OF MEDICINE (IOM) DISCUSSION PAPER, January 2013
Co-authored by Rachel Cohen, DNDi North America Regional Executive Director

Strengthening Mechanisms to Prioritize, Coordinate, Finance, and Execute R&D to Meet Health Needs in Developing Countries


DNDi POLICY BRIEF, April 2012

Transforming Individual Successes into Sustainable Change to Ensure Health Innovation for Neglected Patients:
Why an Essential Health R&D Convention Is Needed

rd-convention-policy-brief-cover thumbnail